Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Maintains $283 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $283 price target.
June 21, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Alnylam Pharmaceuticals with a $283 price target.
The reaffirmation of a Buy rating and a high price target of $283 by Canaccord Genuity is likely to positively impact investor sentiment and could lead to a short-term increase in ALNY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100